How should short rib thoracic dysplasia type 3 (caused by biallelic DYNC2H1 mutations) be diagnosed, counseled, and managed both prenatally and postnatally?

Short Rib Thoracic Dysplasia Type 3 (SRTD3)

All fetuses with suspected SRTD3 should undergo prenatal next-generation skeletal panel gene sequencing or whole exome sequencing at 18-20 weeks gestation (or earlier if detected), followed by immediate referral to a specialist skeletal dysplasia center for comprehensive multidisciplinary management and genetic counseling regarding recurrence risk and pregnancy options 1.

Prenatal Diagnosis

Timing and Imaging

The optimal detection window is 18-20 weeks gestation during routine anatomic ultrasound, though earlier detection at 12-14 weeks is increasingly reported 1, 2, 3. Key ultrasound findings include:

• Short limbs: Femur length or humerus length <5th percentile or >2 SD below mean 1
• Narrow thorax: The hallmark feature of SRTD3 4
• Short ribs: Defining characteristic 4
• Polydactyly: Present in only ~44% of cases, so absence does not exclude diagnosis 4
• Increased nuchal translucency at 10-14 weeks may be an early sign 1

Critical prognostic indicators at 18-20 weeks 1:

• FL/AC ratio <0.16 predicts lethality with high accuracy
• Chest circumference <5th percentile indicates pulmonary hypoplasia
• Chest-to-abdomen ratio <0.6 suggests lethal outcome
• Severe femur shortening (<1st centile) and bowing predict poor prognosis 4

Genetic Testing

Prenatal next-generation skeletal panel gene sequencing or whole exome/genome testing should be offered immediately when skeletal dysplasia is suspected 1. For SRTD3 specifically:

• Look for biallelic DYNC2H1 mutations (compound heterozygous or homozygous) 4, 5, 6
• Testing can be performed on amniotic fluid or chorionic villus sampling 5
• Parental carrier testing should follow to confirm inheritance pattern 5, 6
• Earlier gestational presentation (14-16 weeks) and more significant femur shortening/bowing correlate with worse postnatal prognosis, though genotype-phenotype correlations are unreliable 4

Diagnostic Pitfall

Plain radiographs are not helpful prenatally and should be avoided due to radiation exposure and maternal tissue obscuration 1. Ultrasound remains the primary modality, with MRI as an adjunct if needed 1.

Genetic Counseling

Preconception genetic counseling is mandatory for couples with a previous SRTD3-affected pregnancy 1. Key counseling points:

• 25% recurrence risk with each pregnancy (autosomal recessive inheritance) 5, 3
• Offer preimplantation genetic diagnosis for future pregnancies 1
• Early ultrasound surveillance at 12-13 weeks in subsequent pregnancies enables earlier detection and less traumatic decision-making 2, 3
• Phenotypic severity ranges from mild (compatible with survival) to lethal, with approximately one-third being severe/lethal cases 4

Postnatal Management

All newborns with suspected skeletal dysplasia must be evaluated immediately after delivery, regardless of prenatal diagnosis or predicted prognosis 1. This is non-negotiable even when lethality is suspected, as it allows:

Immediate Actions

1. Clinical examination and skeletal radiographic survey (postnatal skeletal survey is the gold standard) 1
2. Molecular testing confirmation if not done prenatally 1
3. Referral to specialist skeletal dysplasia center for comprehensive management 1

Specialist Center Benefits

The specialist center provides 1:

• Establishment of specific diagnosis and natural history delineation
• Anticipatory screening for associated comorbidities: sleep apnea, hearing loss, renal failure (SRTD3 is a ciliopathy with extraskeletal manifestations in kidneys, liver, retina, and lungs) 1
• Institution of specific therapies when available
• Accurate recurrence risk counseling
• Coordinated prenatal diagnostic planning for future pregnancies

Critical Caveat for Ciliopathy Workup

SRTD3 is part of the ciliopathy spectrum (related to Jeune asphyxiating thoracic dystrophy and short-rib-polydactyly syndromes) 1. Full clinical workup including assessment of kidneys, liver, retina, and lungs is essential to interpret molecular results accurately and provide effective genetic counseling 1.

Phenotypic Variability

SRTD3 shows significant phenotypic heterogeneity 4:

• Mild cases (44%): Compatible with survival, may require minimal intervention
• Moderate cases (22%): Require respiratory support
• Severe/lethal cases (33%): Respiratory insufficiency from pulmonary hypoplasia

Genotype does not reliably predict phenotype, but earlier gestational presentation and more severe femur abnormalities predict worse outcomes 4.

Autopsy Considerations

If termination occurs or neonatal death ensues, full autopsy with skeletal radiographic survey is the mainstay for confirming diagnosis and identifying extraskeletal ciliopathy features 1. Even if parents decline full autopsy, external evaluation with clinical photographs and radiographic survey enables molecular confirmation for future pregnancy planning 1.